BCR-ABL1 kinase: Hunting an elusive target with new weapons

Tomasz Skorski

doi:10.1016/j.chembiol.2011.11.001

BCR-ABL1 kinase: Hunting an elusive target with new weapons

Tomasz Skorski

Temple University

Research output: Contribution to journal › Short survey › peer-review

18 Scopus citations

Abstract

Tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib interfere with ATP-binding pocket to inhibit BCR-ABL1 kinase. A recent report in Cell by Grebien et al. paves the way for a new approach to target BCR-ABL1 kinase by interfering with its SH2-kinase domain interface.

Original language	English
Pages (from-to)	1352-1353
Number of pages	2
Journal	Chemistry and Biology
Volume	18
Issue number	11
DOIs	https://doi.org/10.1016/j.chembiol.2011.11.001
State	Published - Nov 23 2011

Access to Document

10.1016/j.chembiol.2011.11.001

Cite this

@article{87535b701301406ba3a9e67b9a349b74,

title = "BCR-ABL1 kinase: Hunting an elusive target with new weapons",

abstract = "Tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib interfere with ATP-binding pocket to inhibit BCR-ABL1 kinase. A recent report in Cell by Grebien et al. paves the way for a new approach to target BCR-ABL1 kinase by interfering with its SH2-kinase domain interface.",

author = "Tomasz Skorski",

year = "2011",

month = nov,

day = "23",

doi = "10.1016/j.chembiol.2011.11.001",

language = "English",

volume = "18",

pages = "1352--1353",

journal = "Chemistry and Biology",

issn = "1074-5521",

publisher = "Elsevier Ltd.",

number = "11",

}

TY - JOUR

T1 - BCR-ABL1 kinase

T2 - Hunting an elusive target with new weapons

AU - Skorski, Tomasz

PY - 2011/11/23

Y1 - 2011/11/23

N2 - Tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib interfere with ATP-binding pocket to inhibit BCR-ABL1 kinase. A recent report in Cell by Grebien et al. paves the way for a new approach to target BCR-ABL1 kinase by interfering with its SH2-kinase domain interface.

AB - Tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib interfere with ATP-binding pocket to inhibit BCR-ABL1 kinase. A recent report in Cell by Grebien et al. paves the way for a new approach to target BCR-ABL1 kinase by interfering with its SH2-kinase domain interface.

UR - https://www.scopus.com/pages/publications/82255186664

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000297603600006&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1016/j.chembiol.2011.11.001

DO - 10.1016/j.chembiol.2011.11.001

M3 - Short survey

C2 - 22118668

SN - 1074-5521

VL - 18

SP - 1352

EP - 1353

JO - Chemistry and Biology

JF - Chemistry and Biology

IS - 11

ER -

BCR-ABL1 kinase: Hunting an elusive target with new weapons

Abstract

Access to Document

Other files and links

Fingerprint

Cite this